ANAC Share Price

Open 99.23 Change Price %
High 99.27 1 Day 0.00 0.00
Low 99.20 1 Week 0.00 0.00
Close 99.20 1 Month 0.00 0.00
Volume 300 1 Year -12.62 -11.29
52 Week High 119.11
52 Week Low 0.00
ANAC Important Levels
Resistance 2 99.26
Resistance 1 99.24
Pivot 99.22
Support 1 99.16
Support 2 99.14
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC)

ANAC Technical Analysis 4
As on 23rd Jun 2016 ANAC Share Price closed @ 99.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 99.12 & Strong Buy for SHORT-TERM with Stoploss of 81.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
ANAC Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ANAC Other Details
Segment EQ
Market Capital 178077216.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.anacor.com
ANAC Address
ANAC
1020 East Meadow Circle
Palo Alto, CA 94303
United States
Phone: 650-543-7500
Fax: 650-543-7660
ANAC Latest News
Interactive Technical Analysis Chart Anacor Pharmaceuticals, Inc. ( ANAC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Anacor Pharmaceuticals, Inc.
ANAC Business Profile
Anacor Pharmaceuticals, Inc., incorporated in 2000, is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company has discovered, synthesized and developed seven molecules that are in development. Its lead product candidates include two topically administered dermatologic compounds tavaborole and AN2728. In addition, the Company has discovered three compounds that it has out-licensed for further developmentGSK2251052 (GSK '052), AN8194 and AN5568. The Company's clinical pipeline also includes two additional product candidates. AN2718, its second topical antifungal product candidate, has the potential to treat onychomycosis and fungal infections of the skin. AN2898, the Company's second topical anti-inflammatory product candidate, has the potential to treat atopic dermatitis and psoriasis. Tavaborole is the Company’s lead topical antifungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole inhibits an essential fungal enzyme, leucyl-transfer ribonucleic acid (RNA) synthetase (LeuRS), required for protein synthesis. Onychomycosis is primarily caused by dermatophytes, which are fungi that infect the skin, hair or nails. The Phase III program consists of two double-blind, vehicle-controlled trials of approximately 600 patients each. Vehicle refers to the topical solution without the active ingredient. The Company's Phase II clinical trials of tavaborole enabled the Company to define multiple well-tolerated, efficacious doses and a dose-response relationship. The Company has also demonstrated that topical application to the toenails has led to little or no detectable systemic drugs exposure in blood or urine. AN2718 is the Company's second topical antifungal in clinical development for onychomycosis and fungal infections of the skin and utilizes the same mechanism as tavaborole. AN2718 appears to be suited to target organisms that cause common skin and topical fungal infections, including Trichophyton and Candida fungi. The Company's Phase I data for AN2718 has also indicated that AN2718 has a low skin irritation profile across multiple doses and that it would thus be suitable for the treatment of skin fungal infection.